Pulse Biosciences, Inc. (NASDAQ:PLSE – Get Free Report)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $19.96, but opened at $19.19. Pulse Biosciences shares last traded at $19.19, with a volume of 1,747 shares changing hands.
Analyst Ratings Changes
Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a report on Tuesday, August 6th.
Read Our Latest Analysis on PLSE
Pulse Biosciences Stock Down 4.3 %
Institutional Trading of Pulse Biosciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets lifted its position in Pulse Biosciences by 63.6% during the first quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock valued at $66,000 after purchasing an additional 2,952 shares in the last quarter. Quest Partners LLC purchased a new position in Pulse Biosciences during the second quarter valued at approximately $91,000. Price T Rowe Associates Inc. MD purchased a new stake in shares of Pulse Biosciences in the first quarter worth $88,000. Cetera Advisors LLC bought a new stake in shares of Pulse Biosciences during the 1st quarter valued at $109,000. Finally, PNC Financial Services Group Inc. purchased a new position in shares of Pulse Biosciences during the 4th quarter valued at $242,000. 76.95% of the stock is owned by hedge funds and other institutional investors.
About Pulse Biosciences
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Further Reading
- Five stocks we like better than Pulse Biosciences
- How to Choose Top Rated Stocks
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- Transportation Stocks Investing
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
- Trading Stocks: RSI and Why it’s Useful
- Traditional IRA vs. Roth IRA vs. 401(k): A Comparison
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.